Orbital Plasma Cell Tumours

Jónasson, Friðbert

doi:10.1159/000308760

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present only 39 cases of orbital plasma cell tumors have been reported (Dresmy et al, 1977;Fine et al, 1978;Jonasson, 1978;Kuzel and Mausolf, 1978;Levin et al, 1977;Rodman and Font, 1972), and all but four were multiple myelomas. Plasma cell tumors are made more common elsewhere in the head and neck.…”

Section: Discussionmentioning

confidence: 99%

Osteosclerotic Plasmacytoma of maxillary bone (orbital floor)

et al. 1984

View full text Add to dashboard Cite

Plasma cell neoplasms have been classified as multiple myeloma, solitary plasmacytoma and extramedullary plasmacytoma. They are usually considered as osteolytic lesions of bone except for the rare occurrence of osteosclerotic lesions. This paper describes the first reported osteosclerotic plasmacytoma of the maxillary bone and orbital floor. The difficulties in establishing a diagnosis and the relationship to other plasma cell neoplasms are discussed.Osteosclerotic plasmacytomas are a rare variant of plasma cell tumors which usually produce osteolytic lesions rather than bony sclerosis. Sixty-eight patients with the osteosclerotic variant have appeared in the world literature, with an overall incidence of about 1 per cent in a large series of plasma cell neoplasms (Dreidger and Pruzanski, 1979). There have been only six previous cases of solitary osteosclerotic plasmacytomas reported (Morley and Schweiger, 1964; Roberts et al., 1974; Rodriguez et al. 1976; Rushton, 1965; Schneinker, 1938; Brigham Medical Review, 1961) involving spine, sternum, or rib. None have previously been reported in the head and neck area.Plasma cell tumors have been classified into multiple myeloma, solitary plasmacytomas of bone, and extramedullary plasmacytomas. Multiple myeloma is a disseminated plasma cell malignancy characterized by the production of homogeneous immunoglobulins (whole or fragments) which appear in the serum and urine. Plasma cell tumors can also occur as solitary plasmacytomas, usually in bone, but also in soft tissue. With time, most solitary plasmacytomas develop disseminated disease with all the characteristics of multiple myeloma (Wiltshaw, 1976). Extramedullary plasmacytomas arise in soft tissue rather than bone, and primarily occur in the head and neck region. Clinically, they remain localized and less frequently develop into disseminated myeloma.

show abstract

Section: Discussionmentioning

confidence: 99%

Osteosclerotic Plasmacytoma of maxillary bone (orbital floor)

et al. 1984

View full text Add to dashboard Cite

show abstract

“…According to Kyle [16], the median survival is around 20 months and death is usually due to infection or renal insufficiency. Greater care should be taken at the time of surgery because acute renal failure as a result of the anesthetic and relative dehydratation may develop in these patients [17,18]. In our patient, in the preoperative and postoperative period, neither renal problems nor infection occurred and the patient was discharged without an additional deficit.…”

Section: Discussionmentioning

confidence: 68%

Orbital Manifestation of Multiple Myeloma: Case Report

Gönül¹,

İzci²,

Sefali³

et al. 2001

Minim Invasive Neurosurg

View full text Add to dashboard Cite

Orbital involvement is a rare manifestation of multiple myeloma. Therefore, the correct diagnosis and appropriate management are usually difficult and generally require biopsy. We report a 60-year-old woman having multiple myeloma with orbital involvement. Right orbitozygomatic craniotomy was carried out and the mass lesion was removed. After the histological examination, the diagnosis of multiple myeloma was confirmed. The clinical course and the treatment modalities of this entity are discussed in view of the literature.

show abstract

“…Orbital involvement by MM is rare [15, 16, 17, 20, 21, 22, 23, 24, 25]; however, when it occurs, it is frequently the initial manifestation of MM, as in 2 of the 3 cases in this series. Whilst Rodman and Font [16]noted proptosis to be the most frequent presentation of orbital infiltration, this was only found in 1 case, whereas lid swelling and globe displacement from an anterior orbital mass were seen in 2 of the 3 cases.…”

Section: Discussionmentioning

confidence: 87%

Ophthalmic Manifestations of Multiple Myeloma

et al. 2005

View full text Add to dashboard Cite

Purpose: To describe ophthalmic manifestations in a series of patients with multiple myeloma (MM) and review the literature. Design: Retrospective case series. Methods: Review of all cases with ophthalmic manifestations of MM seen at the Department of Ophthalmology, Royal Adelaide Hospital, between 1987 and 2002. Results: Of all patients with MM who were managed at the Royal Adelaide Hospital in the study period, only 8 were referred to the Ophthalmology Department with ophthalmic manifestations. Five males and 3 females with a mean age of 61.25 years (range 42–78) who exhibited ophthalmic manifestations were studied. Six patients (75%) had known MM at the time of their ophthalmic evaluation. Four patients (50%) had neuro-ophthalmic symptoms resulting in diplopia or visual disturbances. Three patients (37.5%) presented with orbital involvement and 1 (12.5%) with hyperviscosity retinopathy. Five patients (62.5%) died within 2 months of their ophthalmic presentation. Conclusion: Ophthalmic manifestations of MM are uncommon and diverse. They may appear at the initial presentation of the disease or occur late in the disease process. Awareness of the possible manifestations may lead to an earlier diagnosis and have a positive influence on the disease course.

show abstract

Orbital Plasma Cell Tumours

Cited by 7 publications

References 6 publications

Osteosclerotic Plasmacytoma of maxillary bone (orbital floor)

Osteosclerotic Plasmacytoma of maxillary bone (orbital floor)

Orbital Manifestation of Multiple Myeloma: Case Report

Ophthalmic Manifestations of Multiple Myeloma

Contact Info

Product

Resources

About